^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SDS-19CAR

i
Other names: SDS-19CAR, anti-CD19 chimeric antigen receptor T cell therapy
Associations
Trials
Company:
Innovative Cellular Therapeutics
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
over2years
Antigen-independent expansion enhances efficacy of CAR-T cells against solid tumor (AACR 2022)
Here, we report the characterization of prostatic acid phosphatase (PAP) as a feasible CAR-T target for prostate cancer and a novel approach, named CoupledCAR, to expand solid tumor-targeting CAR-T cells lacking solid tumor antigens based on the observation of non-transduced T cells proliferating together with CD19 CAR-T cells during the treatment of acute lymphocyte leukemia...Furthermore, we showed that the expansion of solid tumor-targeting CAR-T cells does not depend on CAR/CD3ζ stimulation through direct antigen binding with CAR but enhances the memory status of CAR-T cells and causes little exhaustion. Since the CoupledCAR system does not rely on solid tumor antigens, we propose that it can be utilized in all CAR-T and T cell therapies for the treatment of solid tumors.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • PSAP (Prostatic Acid Phosphatase)
|
SDS-19CAR